Abstract：
Aims: Evaluation of compliance with gynecological multidisciplinary tumor board (MTB) recommendations and its impact. Patients & methods: All patient records discussed in our MTB from 2018 to 2020 were analyzed. Results: We analyzed 437 MTB recommendations concerning 166 patients. Each patient was discussed an average of 2.6 (1.0-4.2) times. Of the 789 decisions, the decision was not followed 102 times (12.9%), corresponding to 85 MTB meetings (19.5%). Of these, 72 recommendations concerned therapeutic changes (70.5%), and 30 concerned non-therapeutic changes (29.5%). Of these 85 MTB decisions, 60 (71%) led to a new MTB submission. Noncompliance with MTB decisions decreased the overall survival (46 vs 138 months; p = 0.003). Conclusion: Improving compliance with MTB decisions is crucial to enhance patient outcomes.
In multidisciplinary tumor board (MTB) meetings, a team of experts discuss the diagnosis and management of cancer patients. While MTB treatment decisions and the reasoning behind them are well documented, the application of these decisions in practice and the associated impact on survival are unknown. This study evaluated compliance with recommendations made during gynecological weekly MTB meetings and the resulting impact on patient management. Between 2018 and 2020, 166 patients were discussed in 437 MTB meetings (each patient was discussed an average of 2.6 times during this period). Noncompliance with the MTB recommendations affected 85/437 MTB meetings (19.5%). Of these, 57 recommendations were therapeutic changes (67.1%) and 28 were non-therapeutic changes (32.9%). In 60 cases (71%), noncompliance with the MTB led to resubmission of the patient data to the MTB. Noncompliance with the board recommendations led to a decrease in patient survival (46 vs 138 months; p = 0.003). This study is expected to raise awareness among practitioners. Considered an essential part of the delivery of high-quality cancer treatment, the implementation of MTB decisions requires further verification.
In multidisciplinary tumor board (MTB) meetings, a team of experts discuss the diagnosis and management of cancer patients. While MTB treatment decisions and the reasoning behind them are well documented, the application of these decisions in practice and the associated impact on survival are unknown. This study evaluated compliance with recommendations made during gynecological weekly MTB meetings and the resulting impact on patient management. Between 2018 and 2020, 166 patients were discussed in 437 MTB meetings (each patient was discussed an average of 2.6 times during this period). Noncompliance with the MTB recommendations affected 85/437 MTB meetings (19.5%). Of these, 57 recommendations were therapeutic changes (67.1%) and 28 were non-therapeutic changes (32.9%). In 60 cases (71%), noncompliance with the MTB led to resubmission of the patient data to the MTB. Noncompliance with the board recommendations led to a decrease in patient survival (46 vs 138 months; p = 0.003). This study is expected to raise awareness among practitioners. Considered an essential part of the delivery of high-quality cancer treatment, the implementation of MTB decisions requires further verification.
摘要：
目的：评价妇科多学科肿瘤委员会（MTB）建议的依从性及其影响。患者和方法：分析了我们2018年至2020年MTB中讨论的所有患者记录。结果：我们分析了有关166例患者的437例MTB建议。每位患者平均讨论2.6（1.0-4.2）次。在789项决定中，该决定没有被遵循102次(12.9%)，相当于85次MTB会议(19.5%)。其中,72项建议涉及治疗变化（70.5%），和30有关非治疗性变化（29.5%）。在这85项MTB决策中，60（71％）导致新的MTB提交。不遵守MTB决定降低了总生存期（46vs138个月；p=0.003）。结论：提高对MTB决策的依从性对于提高患者预后至关重要。
在多学科肿瘤委员会（MTB）会议上，一组专家讨论癌症患者的诊断和管理。虽然MTB治疗决定及其背后的原因是有据可查的，这些决定在实践中的应用以及对生存的相关影响尚不清楚.这项研究评估了对妇科每周MTB会议期间提出的建议的依从性以及对患者管理的影响。在2018年至2020年之间，在437次MTB会议中讨论了166名患者（在此期间，每位患者平均讨论了2.6次）。不遵守MTB建议影响了85/437次MTB会议（19.5％）。其中,57项建议为治疗性改变（67.1%），28项为非治疗性改变（32.9%）。在60例（71％）中，不遵守MTB导致患者数据重新提交给MTB.不遵守委员会的建议导致患者生存期下降（46vs138个月；p=0.003）。这项研究有望提高从业人员的认识。被认为是提供高质量癌症治疗的重要组成部分，MTB决定的执行需要进一步核实。
在多学科肿瘤委员会（MTB）会议上，一组专家讨论癌症患者的诊断和管理。虽然MTB治疗决定及其背后的原因是有据可查的，这些决定在实践中的应用以及对生存的相关影响尚不清楚.这项研究评估了对妇科每周MTB会议期间提出的建议的依从性以及对患者管理的影响。在2018年至2020年之间，在437次MTB会议中讨论了166名患者（在此期间，每位患者平均讨论了2.6次）。不遵守MTB建议影响了85/437次MTB会议（19.5％）。其中,57项建议为治疗性改变（67.1%），28项为非治疗性改变（32.9%）。在60例（71％）中，不遵守MTB导致患者数据重新提交给MTB.不遵守委员会的建议导致患者生存期下降（46vs138个月；p=0.003）。这项研究有望提高从业人员的认识。被认为是提供高质量癌症治疗的重要组成部分，MTB决定的执行需要进一步核实。
